{"schema_version":"secwatch.filing_event.v1","accession":"0001932393-23-000124","form_type":"8-K","ticker":"GEHC","cik":"0001932393","company_name":"GE HealthCare Technologies Inc.","filed_at":"2023-10-31T23:59:59+00:00","discovered_at":"2026-05-14T18:03:31.418218+00:00","generated_at":"2026-06-09T05:01:59.564164+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"GE HealthCare Q3 revenue +6% organic; raises low end of adjusted EPS guidance","bullets":["Revenue $4.8B, up 5% reported and 6% organic YoY; net income $375M vs $487M.","Adjusted EPS $0.99 vs standalone adjusted $0.87 (+14%); GAAP EPS $0.83 vs $1.07.","Adjusted EBIT margin 15.4% (+120 bps vs standalone 14.2%); free cash flow $570M (+$22M YoY).","Full-year adjusted EPS raised to $3.75-$3.85 (prior $3.70-$3.85); organic growth 6%-8%.","Imaging +5%, Ultrasound -1%, Patient Care Solutions +9%, Pharmaceutical Diagnostics +13%."],"urls":{"canonical":"https://secwatch.observer/filing/0001932393-23-000124","json":"https://secwatch.observer/filing/0001932393-23-000124.json","markdown":"https://secwatch.observer/filing/0001932393-23-000124.md","text":"https://secwatch.observer/filing/0001932393-23-000124.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000124/0001932393-23-000124-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000124/gehc-20231031.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-09T05:01:59.564164+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"521047311b32848e4c675eb99027f809b4101a5d","claim":"GE HealthCare Technologies Inc. reported third quarter ended September 30, 2023 results: revenue $4.8 billion, net income $375 million, EPS $0.83. Guidance raised.","evidence_excerpt":"management. We remain confident in our 2023 outlook as we continue to innovate for customers and patients.” Third Quarter 2023 Total Company Financial Performance • Revenues of $4.8 billion increased 5% reported and 6% on an Organic basis* year-over-year, driven by volume and price. • Total company book-to-bill, defined as Total orders divided by Total revenues, was","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1932393/000193239323000124/0001932393-23-000124-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"third quarter ended September 30, 2023"},{"label":"Revenue","value":"$4.8 billion"},{"label":"Net income","value":"$375 million"},{"label":"EPS","value":"$0.83"},{"label":"Guidance","value":"raised"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}